Adverum Biotechnologies Inc (NAS:ADVM)
$ 4.8 -0.22 (-4.38%) Market Cap: 99.85 Mil Enterprise Value: 24.45 Mil PE Ratio: 0 PB Ratio: 0.69 GF Score: 34/100

Adverum Biotechnologies Inc ADVM-022 Update Call Transcript

Jul 22, 2021 / 08:30PM GMT
Release Date Price: $30.6 (-2.86%)
Operator

Good afternoon, and welcome to the Adverum Biotechnologies Conference Call. (Operator Instructions) As a reminder, this conference call is being recorded.

I would now like to hand the call over to Amy Figueroa, Vice President of Investor Relations and Corporate Communications of Adverum. Please go ahead.

Amy Figueroa
Adverum Biotechnologies, Inc. - VP of IR & Corporate Communications

Thank you, Paul.

Good afternoon. Thank you for joining today's call to discuss an update on the ADVM-022 gene therapy program. A copy of the press release is available in the Investor Relations section of our corporate website at www.adverum.com. Please note that a replay of today's call will be available on the Events and Presentations section of our website.

Joining me today is Dr. Laurent Fischer, President and Chief Executive Officer; and Dr. Julie Clark, Chief Medical Officer. In addition, we are joined by Dr. Szilárd Kiss, Associate Professor in Ophthalmology and Member of

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot